Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical Inc (AMIX) is a pioneer in developing catheter-based neural sensing technologies for neurological disorders. This page provides centralized access to official company announcements, regulatory updates, and breakthrough developments in microchip-enabled medical diagnostics.
Investors and industry professionals will find timely updates on AMIX's R&D milestones, strategic partnerships, and preclinical progress with its proprietary neural signal detection platform. The curated news feed ensures accurate tracking of advancements in minimally invasive neural disorder treatments.
Key updates include regulatory submissions, research collaborations, technology validations, and intellectual property developments. All content is sourced directly from company filings and authorized communications to maintain compliance and reliability.
Bookmark this page for streamlined monitoring of AMIX's progress in redefining neurological diagnostics through its microchip-integrated catheter technology. Check back regularly for verified updates on this development-stage innovator's journey toward clinical impact.
Autonomix Medical (NASDAQ: AMIX) has announced the engagement of leading medical experts to guide its U.S. clinical and regulatory pathway for pancreatic cancer pain treatment. The advisory team includes former Society of Interventional Radiology Past Presidents Dr. Michael Brunner and Dr. Katharine Krol, along with Dr. Patricio Polanco and Dr. Nikola Cesarovic.
The company is preparing for FDA De Novo submission in 2026, with plans to initiate U.S. clinical studies in 2025. This strategic move aims to ensure their pre-clinical and clinical studies align with FDA requirements for their first-in-class technology in nervous system disease diagnosis and treatment.
Autonomix Medical (NASDAQ: AMIX) announced that its abstract on nerve-targeted treatment technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO). The presentation, titled 'Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study,' will be presented at the conference scheduled for April 13-16, 2025, in Rotterdam, Netherlands. The study's authors include Dr. Robert S. Schwartz, Chief Medical Officer of Autonomix Medical, and Dr. Askar Uktamovich Sabirov from AKFA Medline Hospital.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnostics and treatment technologies, has announced an inducement stock option grant. The Compensation Committee approved on March 17, 2025, options to purchase 7,500 shares of common stock for a new non-executive employee.
The stock options, granted under Nasdaq Rule 5635(c)(4), have a ten-year term and will vest in four equal annual installments. The exercise price matches the closing price of Autonomix's common stock on the Nasdaq Capital Market as of March 17, 2025. The grant serves as part of the employee's compensation package and was provided as an inducement for their employment.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. patent 12,217,863 by the USPTO for its medical devices with circuitry for capturing and processing physiological signals. The patent protects the company's proprietary technology for real-time physiological monitoring across various applications including heart mapping, arterial mapping, and nervous system monitoring.
The company's innovative platform features a catheter-based microchip sensing array antenna that can detect neural signals with up to 3,000 times greater sensitivity than current technologies. Combined with proprietary RF ablation technology, it enables precise targeting and elimination of overactive nerves.
Autonomix plans to submit an IDE and begin U.S. clinical trials in 2025 to commercialize their Sensing and RF Ablation System for treating pancreatic cancer pain. The company's patent portfolio now includes over 80 issued patents and 40 pending applications.
Autonomix Medical (NASDAQ: AMIX) has achieved a significant milestone by completing the integration of the Apex 6 Radiofrequency Generator into its transvascular treatment platform, now branded as the Autonomix Sensing and RF Ablation System. This advancement keeps the company on schedule for its Investigational Device Exemption (IDE) submission and potential U.S. clinical trials initiation in 2025.
The integration follows the July 2024 licensing agreement with RF Innovations for the FDA-cleared Apex 6 Generator technology. The company aims to develop a treatment for pancreatic cancer pain, with the system showing promising early clinical results. Autonomix is working with RF Innovations' manufacturing partner to facilitate equipment development, targeting FDA De Novo clearance for commercialization in the U.S. market.
Autonomix Medical (NASDAQ: AMIX) announced the acceptance of their abstract for poster presentation at the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting in Nashville, Tennessee, from March 29-April 2, 2025.
The presentation, titled 'Pain Mitigation in Pancreatic Adenocarcinoma: An Interim Analysis of Neurolysis via Transvascular RF Energy-Based Ablation', will be delivered by Dr. Bela Kis, Chief of Interventional Radiology at Moffitt Cancer Center, on Monday, March 31, at 12:10 PM CT.
The SIR conference, representing over 8,000 practicing interventional radiology professionals, focuses on advancing image-guided therapies and improving patient care through emerging methodologies and cutting-edge technologies.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system diagnosis and treatment technologies, has announced its participation in the LSI USA '25 Emerging Medtech Summit.
CEO Brad Hauser will deliver a presentation on March 18, 2025, at 7:35 AM PT. The company's management team will also be available for one-on-one meetings with qualified registered investors during the conference.
Autonomix Medical (NASDAQ: AMIX) has been selected to present its catheter-based technology and initial findings from its ongoing human clinical trial in pancreatic cancer pain patients at the 2025 Cardiovascular Research Technologies (CRT) Annual Meeting. The presentation, titled 'Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain: First Results From The Elpis Study,' will be delivered by Dr. Robert Schwartz, Chief Medical Officer, on March 10, 2025.
The presentation will be featured in the Innovation HUB session, which showcases innovative products and services that haven't yet been fully market-released, including early-stage/prototype, pre-clinical, first-in-human, and CE Mark technologies. The CRT Annual Meeting, scheduled for March 8-11, 2025, in Washington, DC, is a prominent educational forum focusing on new cardiovascular technology and procedures.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in precision nerve-targeted treatments, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. Brad Hauser, President and CEO, presented the company's top five reasons why investors and industry professionals should monitor Autonomix in 2025. The presentation is now available for viewing on the company's website and through a direct webcast link.
Autonomix Medical (NASDAQ: AMIX) reported Q3 FY2025 financial results and corporate updates. The company is advancing its proof-of-concept clinical trial for pancreatic cancer pain treatment, with topline data expected in 1H 2025. Key achievements include expanding intellectual property, strengthening regulatory teams, and achieving design lock for RF ablation catheter.
Financial highlights show a net loss of $2.7 million for Q3, compared to $3.1 million in the previous year. The company secured a $10 million public offering to extend its cash runway. R&D expenses increased to $1.0 million from $0.7 million year-over-year, while G&A expenses decreased to $1.7 million from $2.2 million.
The company's technology platform features a catheter-based microchip sensing array with 3,000 times greater sensitivity than current technologies. Autonomix aims for potential FDA clearance by 2027, with US clinical trials planned for 2025.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
